3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
27
Unknown
3
Withdrawn
2
Terminated
2
Recruiting
2
Not yet recruiting
1
Enrolling by invitation
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Thyroid Carcinoma, Anaplastic
1
Crohn Disease
1
Interventions
Cyclophosphamide
128
Cisplatin
119
Radiotherapy
111
pembrolizumab
110
Paclitaxel
96
Gemcitabine
96
Carboplatin
96
Nivolumab
76
Magnetic Resonance Spectroscopy
76
Bevacizumab
76
Fluorouracil
74
Dexamethasone
73
Radiosurgery
66
Docetaxel
59
Rituximab
58
Leucovorin
57
Oxaliplatin
55
Capecitabine
55
Doxorubicin
52
fludarabine
51
Biopsy
48
durvalumab
44
Cytarabine
44
Drug Therapy
43
Etoposide
42
fludarabine phosphate
40
Pemetrexed
40
Radiation
39
atezolizumab
36
Lenalidomide
35
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Withdrawn
×
Interventional
×
Adalimumab
×
Clear all
NCT04655807
2025-04-27
DUET
Janssen Research & Development, LLC
Phase 2
Withdrawn
NCT02516774
2016-01-26
TAM-RT
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1
Withdrawn